2-(trifluoromethylsulfonyloxy)-11-(4-methyl-1-piperazinyl)-5H-dibenzo[b,e][1,4]diazepine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯二氮卓类
• 英文名称: 2-(trifluoromethylsulfonyloxy)-11-(4-methyl-1-piperazinyl)-5H-dibenzo[b,e][1,4]diazepine
• 英文别名: GMC 1-169；[6-(4-methylpiperazin-1-yl)-11H-benzo[b][1,4]benzodiazepin-8-yl] trifluoromethanesulfonate
• 化学式: C₁₉H₁₉F₃N₄O₃S
• 分子量: 440.446
• InChiKey: XKXPMSXRABANAG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  30
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.32
• 拓扑面积：
  82.6
• 氢给体数：
  1
• 氢受体数：
  9

反应信息

• 作为产物：
  描述：

  2-hydroxy-5,10-dihydro-11-dioxodibenzo<1,4>diazepine 在 N,N-二甲基苯胺 、 三乙胺 、 三氯氧磷 作用下， 以 1,4-二氧六环 、 甲苯 为溶剂， 反应 6.0h， 生成 2-(trifluoromethylsulfonyloxy)-11-(4-methyl-1-piperazinyl)-5H-dibenzo[b,e][1,4]diazepine
  参考文献：
  名称：

  Synthesis and Pharmacological Evaluation of Triflate-Substituted Analogues of Clozapine:  Identification of a Novel Atypical Neuroleptic

  摘要：

  The trifluoromethanesulonyloxy (TfO) analogues 3 and 4 of 8-chloro-11-(4-methyl-1-piperazinyl)-5H-dibenzo[b,e][1,4]diazepine (clozapine, 1) and its 2-chloro isomer (iso-clozapine, 2), respectively, were synthesized via their OMe and OH analogues with the conventional synthetic method of the tricyclic dibenzodiazepines and evaluated pharmacologically along with their parent drugs. The binding profile of the 2-OTf analogue (4) is comparable to the binding profile of 1, although the affinity for the dopamine (DA) D-2 receptors is higher (IC50 values are 31 nM and 330 nM for compounds 4 and 1, respectively). Interestingly, no notable affinity for muscarinic receptors could be detected in compound 4. On the contrary, the 3-OTf analogue 3 only displayed affinity for muscarinic M-1 receptors (IC50 value 35 nM) and no affinity (IC50 value > 500 nM) for the other receptors tested. The 10 mu mol/kg sc dose, but nod the 10 mu mol/kg po dose, of compound 4 stimulated the output of DA, Increases of 80% and 35% in DOPAC output from the dorsal striatum were seen after sc and po administrations of 10 mu mol/kg of compound 4, respectively. Doses up to 100 mu mol/kg of compound 3 had no effect on either parameter. Doses up to 100 mu mol/kg of compound 4 were not cataleptogenic, but significantly decreased apomorphine-induced locomotor activity. In conclusion, compound 4 (GMC1-169) is a new clozapine-like neuroleptic candidate, which is lacking anticholinergic properties and displays a higher potency, as compared to clozapine (1) itself.

  DOI：

  10.1021/jm9704457

文献信息

• [EN] NEW SULFONE ESTER ANALOGUES OF iso-CLOZAPINE AND RELATED STRUCTURES: ATYPICAL NEUROLEPTICS<br/>[FR] ESTERS DE SULFONE CONSTITUANT DE NOUVEAUX ANALOGUES D'ISO-CLOZAPINE ET STRUCTURES APPARENTEES: NEUROLEPTIQUES ATYPIQUES
  申请人：WIKSTRÖM, Håkan

  公开号：WO1996029316A1

  公开（公告）日：1996-09-26

  (EN) A compound of formula (I), or pharmaceutically acceptable acid addition salts thereof, wherein R1 is H, (C1-C8) alkyl or haloalkyl or hydroxyalkyl, alkenyl, alkynyl, cyclopropylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl; R2 is H, (C1-C8) alkyl, alkenyl, alkynyl, cyclopropylalkyl or (C1-C8) haloalkyl, hydroxyalkyl, hydroxyalkyloxyalkyl or 1-(alkyl-2-imidazolidinone); X is NH, NR1, O, S, SO, SO2. The compounds of this invention possess affinity to one or several receptor systems, e.g. DA (D1-D4), $g(a)1, muscarinic (M1-M4) and 5-HT (5-HT2A, 5-HT2C and 5-HT7). The central nervous system disorders to be treated with the compounds of the present invention include psychoses-schizophrenia, autism, Tourette's syndrome, restless legs, Huntington's chorea, motion sickness, nausea, vomiting and severe anxiety.(FR) Composé de formule (I) ou ses sels à addition d'acide pharmaceutiquement acceptables, où R1 est H, haloalkyle, hydroaxyalkyle ou alkyle (C1-C8), alcényle, alcynyle, cyclopropylalkyle, aryle, arylalkyle, hétéroaryle, hétéroarylalkyle; R2 est H, alcényle, alcynyle, cyclopropylalkyle, alkyle (C1-C8) ou hydroxyalcyle, hydroxyalkyloxyalkyle, haloalkyle (C1-C8) ou 1-(alkyl-2-imidazolidinone); X est NH, NR1, O, S, SO, ou SO2. Les composés réalisés selon cette invention possèdent une affinité avec un ou plusieurs systèmes récepteurs, par exemple DA (D1-D4), $g(a)1, muscariniques (M1-M4) et 5-HT (5-HT2A, 5-HT2C et 5-HT7). Les troubles du système nerveux central pouvant être traités par les composés réalisés selon la présente invention sont notamment la psychose schizophrénique, l'autisme, le syndrome de Tourette, les impatiences des membres inférieurs, la chorée de Huntington, le mal des transports, la nausée, le vomissement et l'anxiété grave.

  化合物式(I)或其药学上可接受的酸盐，其中R1是H，(C1-C8)烷基或卤代烷基或羟基烷基，烯基，炔基，环丙基烷基，芳基，芳基烷基，杂环芳基，杂环芳基烷基; R2是H，(C1-C8)烷基，烯基，炔基，环丙基烷基或(C1-C8)卤代烷基，羟基烷基，羟基烷氧基烷基或1-(烷基-2-咪唑啉酮); X是NH，NR1，O，S，SO，SO2。本发明的化合物具有与一个或多个受体系统的亲和力，例如DA（D1-D4），$g(a)1，肌动蛋白受体（M1-M4）和5-HT（5-HT2A，5-HT2C和5-HT7）。本发明化合物可用于治疗中枢神经系统疾病，包括精神病-精神分裂症，自闭症，图雷特综合症，不宁腿综合症，亨廷顿舞蹈症，晕动病，恶心，呕吐和严重焦虑。
• Amino substituted diaryl[a,d]cycloheptene analogs as muscarinic agonists and methods of treatment of neuropsychiatric disorders
  申请人：Ek Fredrik

  公开号：US20050192268A1

  公开（公告）日：2005-09-01

  Disclosed herein are analogs of clozapine and pharmaceutically acceptable salts, esters, amides, or prodrugs thereof; methods of synthesizing the analogs; and methods of using the analogs for treating neuorpsychiatric disorders. In some embodiments, the analogs are amino substituted diaryl[a,d]cycloheptenes.

  本文披露了氯氮平的类似物及其药用可接受的盐，酯，酰胺或前药；合成类似物的方法；以及使用类似物治疗神经精神障碍的方法。在某些实施例中，类似物是氨基取代的二芳基[a，d]环庚烯。
• Amino bustituted diaryl[a,d]cycloheptene analogs as muscarinic agonists and methods of treatment of neuropsychiatric disorders
  申请人：Ek Fredrik

  公开号：US20060199798A1

  公开（公告）日：2006-09-07

  Disclosed herein are analogs of clozapine and pharmaceutically acceptable salts, esters, amides, or prodrugs thereof; methods of synthesizing the analogs; and methods of using the analogs for treating neuorpsychiatric disorders. In some embodiments, the analogs are amino substituted diaryl[a,d]cycloheptenes.

  本文公开了氯氮平的类似物及其药学上可接受的盐、酯、酰胺或前药；合成这些类似物的方法；以及使用这些类似物治疗神经精神障碍的方法。在某些实施例中，这些类似物是氨基取代的二芳基[a，d]环庚烯。
• AMINO SUBSTITUTED DIARYL[a,d]CYCLOHEPTENE ANALOGS AS MUSCARINIC AGONISTS AND METHODS OF TREATMENT OF NEUROPSYCHIATRIC DISORDERS
  申请人：Ek Fredrik

  公开号：US20090239840A1

  公开（公告）日：2009-09-24

  Disclosed herein are analogs of clozapine and pharmaceutically acceptable salts, esters, amides, or prodrugs thereof; methods of synthesizing the analogs; and methods of using the analogs for treating neuorpsychiatric disorders. In some embodiments, the analogs are amino substituted diaryl[a,d]cycloheptenes.

  本文披露了氯氮平的类似物及其药学上可接受的盐、酯、酰胺或前药；合成类似物的方法；以及使用类似物治疗神经精神障碍的方法。在某些实施例中，这些类似物是氨基取代的二芳基[a，d]环庚烯。
• Use of N-desmethylclozapine and related compounds as dopamine stabilizing agents
  申请人：Burstein S. Ethan

  公开号：US20060252744A1

  公开（公告）日：2006-11-09

  Disclosed herein is the use of N-desmethylclozapine (NDMC) and related compounds to treat a variety of neuropsychiatric diseases including psychosis. It is shown that NDMC and related compounds are agonists or partial agonists at D2 and D3 dopamine receptors and thus may be effective as a dopamine stabilizing agent, allowing it to be used to treat or provide reduced incidence of Extrapyramidal symptoms (EPS) and/or tardive dyskinesias (TD). Also disclosed is administering NDMC and related compounds in combination with other anti-psychotic agents.

  本文披露了使用N-去甲基氯氮平（NDMC）及相关化合物治疗多种神经精神疾病，包括精神病的方法。研究表明，NDMC及相关化合物是D2和D3多巴胺受体的激动剂或部分激动剂，因此可能作为多巴胺稳定剂起作用，从而可用于治疗或减少肌张力障碍症状（EPS）和/或迟发性运动障碍（TD）。本文还披露了将NDMC及相关化合物与其他抗精神病药物联合使用的方法。